Related Experiment Videos
Botulinum toxin and cerebral palsy: time for reflection?
M Gough1, C Fairhurst, A P Shortland
1One Small Step Gait Analysis Laboratory, Guy's Hospital, London, UK. martin.gough@gstt.sthames.nhs.uk
Developmental Medicine and Child Neurology
|September 22, 2005
Summary
Early botulinum toxin A (BTX-A) injections for cerebral palsy (CP) spasticity may improve short-term function but lack long-term outcome data. A cautious approach is advised until more evidence is available.
Area of Science:
- Pediatric Neurology
- Rehabilitation Medicine
- Biologics and Drug Therapy
Background:
- Botulinum toxin A (BTX-A) is increasingly used for early spasticity management in ambulant children with cerebral palsy (CP).
- Aims include improving function, promoting muscle growth, and delaying surgery.
- Limited evidence exists regarding the long-term outcomes of BTX-A injections in this population.
Purpose of the Study:
- To evaluate the long-term effects of early BTX-A injections on function and muscle growth in children with CP.
- To address concerns about potential adverse long-term effects on muscle function.
- To inform clinical practice regarding the cautious use of BTX-A.
Main Methods:
- Review of existing literature on BTX-A use in pediatric CP.
- Analysis of functional outcomes and muscle growth data.
- Consideration of spasticity versus muscle weakness in management strategies.
Main Results:
- BTX-A may offer short-term functional improvements in spasticity.
- Potential for adverse long-term effects on muscle growth and function exists.
- Current evidence on long-term outcomes remains insufficient.
Conclusions:
- A cautious approach to early BTX-A use is recommended for ambulant children with spastic diplegic CP.
- Objective outcome measures in multidisciplinary settings are crucial.
- Further research on long-term outcomes is necessary before widespread early adoption.